MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
stock options
$86K
(-69.40%↓ Y/Y)
Net cash provided by
financing activities
$64K
(-76.64%↓ Y/Y)
Canceled cashflow
$22K
Net decrease in
cash, cash...
-$61,033K
(-15.63%↓ Y/Y)
Canceled cashflow
$64K
Share-based compensation
expense
$25,173K
(-8.04%↓ Y/Y)
Inventory
-$18,806K
(-34.36%↓ Y/Y)
Net income/(loss)
$18,656K
(120.23%↑ Y/Y)
Depreciation expense
$291K
(-34.75%↓ Y/Y)
Payments of employee tax
withholding related to...
$22K
(214.29%↑ Y/Y)
Net cash used in
operating activities
-$60,966K
(-14.15%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$131K
(-136.49%↓ Y/Y)
Canceled cashflow
$62,926K
Accounts receivable
$74,068K
(349.56%↑ Y/Y)
Accrued expenses and
other liabilities
-$31,166K
(-3.35%↓ Y/Y)
Prepaid and other
current assets
$11,270K
Accounts payable
-$7,741K
(-146.32%↓ Y/Y)
Back
Back
Cash Flow
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
source: myfinsight.com